Professor Angela J. Russell gained her M.Chem. degree from the University of Oxford in 2000 and her D.Phil. in Organic Chemistry in 2004 under the joint supervision of Steve Davies and Tim Perera from Yamanouchi plc (now Astellas Pharma Inc.). In March 2006 she became a Departmental Research Lecturer in Organic Chemistry and in July 2007 was awarded a prestigious Research Councils’ UK Fellowship in Medicinal Chemistry jointly between the Departments of Chemistry and Pharmacology in Oxford. In 2012 she was appointed as University Lecturer, and in 2014 became an Associate Professor of Medicinal Chemistry. Angela’s research interests broadly encompass the development of small molecules to control developmental processes. Angela has realised several successful multidisciplinary research collaborations, including identifying small molecules to upregulate utrophin for the treatment of Duchenne Muscular Dystrophy, developing novel inhibitors and activators of developmental signaling pathways and new anti-cancer agents. Since 2005 Angela has initiated a number of collaborative programmes involving the discovery and development of small molecules to manipulate stem cell fate. Angela’s work has resulted in >60 publications and patent filings to date.  In addition, Angela has founded two University spin out companies: MuOx Ltd in 2012, which was acquired by Summit plc in 2013, and OxStem Ltd in 2014. Professor Angela J. Russell gained her M.Chem. degree from the University of Oxford in 2000 and her D.Phil. in Organic Chemistry in 2004 under the joint supervision of Steve Davies and Tim Perera from Yamanouchi plc (now Astellas Pharma Inc.). In March 2006 she became a Departmental Research Lecturer in Organic Chemistry and in July 2007 was awarded a prestigious Research Councils’ UK Fellowship in Medicinal Chemistry jointly between the Departments of Chemistry and Pharmacology in Oxford. In 2012 she was appointed as University Lecturer, and in 2014 became an Associate Professor of Medicinal Chemistry. Angela’s research interests broadly encompass the development of small molecules to control developmental processes. Angela has realised several successful multidisciplinary research collaborations, including identifying small molecules to upregulate utrophin for the treatment of Duchenne Muscular Dystrophy, developing novel inhibitors and activators of developmental signaling pathways and new anti-cancer agents. Since 2005 Angela has initiated a number of collaborative programmes involving the discovery and development of small molecules to manipulate stem cell fate. Angela’s work has resulted in >60 publications and patent filings to date.  In addition, Angela has founded two University spin out companies: MuOx Ltd in 2012, which was acquired by Summit plc in 2013, and OxStem Ltd in 2014.

fermentation